Total Payments
$45,875
2024 Payments
$88.28
Companies
7
Transactions
11
Medicare Patients
23,193
Medicare Billing
$5.4M
Payment Breakdown by Category
Research$45,587 (99.4%)
Education$169.30 (0.4%)
Food & Beverage$88.28 (0.2%)
Other$31.25 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $45,587 | 3 | 99.4% |
| Education | $169.30 | 6 | 0.4% |
| Food and Beverage | $88.28 | 1 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31.25 | 1 | 0.1% |
Payments by Type
Research
$45,587
3 transactions
General
$288.83
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $45,587 | 3 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $99.99 | 1 | $0 (2021) |
| Genentech USA, Inc. | $88.28 | 1 | $0 (2024) |
| Seattle Genetics, Inc. | $36.87 | 3 | $0 (2018) |
| PFIZER INC. | $31.25 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $20.52 | 1 | $0 (2022) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $88.28 | 1 | Genentech USA, Inc. ($88.28) |
| 2022 | $20.52 | 1 | E.R. Squibb & Sons, L.L.C. ($20.52) |
| 2021 | $111.91 | 2 | SANOFI-AVENTIS U.S. LLC ($99.99) |
| 2019 | $2,971 | 1 | Celgene Corporation ($2,971) |
| 2018 | $22,836 | 5 | Celgene Corporation ($22,768) |
| 2017 | $19,848 | 1 | Celgene Corporation ($19,848) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/22/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $88.28 | General |
| Category: BioOncology | ||||||
| 10/10/2022 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Education | In-kind items and services | $20.52 | General |
| Category: Hematology | ||||||
| 09/27/2021 | SANOFI-AVENTIS U.S. LLC | ELITEK (Biological) | Education | In-kind items and services | $99.99 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/05/2019 | Celgene Corporation | Revlimid (Drug) | — | Cash or cash equivalent | $2,970.50 | Research |
| Study: A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) • Category: Hematology / Oncology | ||||||
| 08/28/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 08/09/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 06/30/2018 | PFIZER INC. | BOSULIF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $31.25 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 04/09/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 01/05/2018 | Celgene Corporation | Revlimid (Drug) | — | Cash or cash equivalent | $22,768.00 | Research |
| Study: CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu • Category: Hematology / Oncology | ||||||
| 02/01/2017 | Celgene Corporation | Revlimid (Drug) | — | Cash or cash equivalent | $19,848.00 | Research |
| Study: CC-5013-NHL-008 • Category: Hematology / Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu | Celgene Corporation | $22,768 | 1 |
| CC-5013-NHL-008 | Celgene Corporation | $19,848 | 1 |
| A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) | Celgene Corporation | $2,971 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 68 | 5,267 | 92,616 | $7.0M | $1.6M |
| 2022 | 73 | 5,562 | 119,935 | $5.1M | $1.1M |
| 2021 | 94 | 6,238 | 152,034 | $6.2M | $1.4M |
| 2020 | 91 | 6,126 | 130,832 | $5.8M | $1.3M |
Total Patients
23,193
Total Services
495,417
Medicare Billing
$5.4M
Procedure Codes
326
All Medicare Procedures & Services
326 procedure records from CMS Medicare Utilization — Page 1 of 14
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 15 | 19,800 | $2.7M | $750,614 | 27.8% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 6,400 | $935,400 | $267,736 | 28.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 14 | 5,460 | $382,380 | $98,842 | 25.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 396 | 996 | $300,633 | $91,272 | 30.4% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 11 | 3,218 | $624,292 | $74,288 | 11.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 84 | 180 | $68,146 | $24,508 | 36.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 10,160 | $213,360 | $23,825 | 11.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 64 | 219 | $182,749 | $22,166 | 12.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 460 | 1,965 | $68,775 | $14,912 | 21.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 403 | 1,383 | $85,746 | $14,295 | 16.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 39 | 216 | $53,819 | $12,132 | 22.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 70 | 222 | $67,488 | $10,703 | 15.9% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 114 | 606 | $109,686 | $10,257 | 9.4% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 147 | 1,080 | $58,320 | $9,842 | 16.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 122 | 138 | $24,916 | $8,481 | 34.0% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 21 | 484 | $84,700 | $8,452 | 10.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 102 | 128 | $21,504 | $7,938 | 36.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 13 | 19,890 | $119,340 | $7,929 | 6.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 79 | $23,239 | $7,216 | 31.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 313 | 866 | $16,454 | $7,199 | 43.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $24,941 | $6,925 | 27.8% |
| 86334 | Immunologic analysis technique on serum (immunofixation) | Office | 2023 | 124 | 290 | $44,950 | $6,348 | 14.1% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 231 | 455 | $26,390 | $6,054 | 22.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 81 | 488 | $51,240 | $5,792 | 11.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 91 | 396 | $36,828 | $4,119 | 11.2% |
About Dr. Scott Cross, MD
Dr. Scott Cross, MD is a Specialist healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1922003763.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Cross, MD has received a total of $45,875 in payments from pharmaceutical and medical device companies, with $88.28 received in 2024. These payments were reported across 11 transactions from 7 companies. The most common payment nature is "" ($45,587).
As a Medicare-enrolled provider, Cross has provided services to 23,193 Medicare beneficiaries, totaling 495,417 services with total Medicare billing of $5.4M. Data is available for 4 years (2020–2023), covering 326 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Norfolk, VA
- Active Since 06/17/2005
- Last Updated 04/11/2011
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1922003763
Products in Payments
- Revlimid (Drug) $45,587
- ELITEK (Biological) $99.99
- Tecentriq (Biological) $88.28
- ADCETRIS (Biological) $36.87
- BOSULIF (Drug) $31.25
- Pomalyst (Drug) $20.52
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Norfolk
Edward George, Md, MD
Specialist — Payments: $722,185
Specialist $722,185
Dr. Ingrid Loma-Miller, Md, MD
Specialist — Payments: $458,577
Specialist $458,577
Dr. Mark Fontana, Md, MD
Specialist — Payments: $37,884
Specialist $37,884
Paul Conkling, Md, MD
Specialist — Payments: $24,936
Specialist $24,936
Dr. Robert Schnarrs, Md, MD
Specialist — Payments: $21,616
Specialist $21,616
Burton Alexander, Md, MD
Specialist — Payments: $18,609
Specialist $18,609